[Antitumor concomitant immunity: a possible metastasis control mechanism]

Area of Science:

• Immunology
• Oncology
• Tumor Biology

Context:

• Concomitant immunity (CI) is an immunological phenomenon where a secondary tumor implant is rejected.
• This study investigates CI in spontaneous tumors and its association with metastasis.
• Previous research often focused on immunogenic tumors and specific immune cell involvement.

Purpose:

• To investigate concomitant immunity (CI) in association with spontaneous tumors, with or without metastases.
• To determine the immunological mechanisms underlying CI, particularly the role of T lymphocytes, NK cells, and macrophages.
• To explore the relationship between CI, inflammation, and metastasis in syngeneic tumor models.

Summary:

• Syngeneic tumors in BALB/c mice, even those with undetectable immunogenicity, induced CI, inhibiting secondary tumor implants.
• CI was observed in nude mice and silica-treated mice, ruling out T lymphocytes, NK cells, and macrophages.
• Tumor growth inhibition was due to cytostasis (dormancy) rather than rejection, with no host cell infiltration.
• Local inflammation abrogated CI, promoting tumor growth, while foreign body inflammation inhibited tumor growth.
• Non-metastatic mammary tumors induced stronger CI and prevented metastases, unlike metastatic counterparts.

Impact:

• This research reveals a non-immune mediated mechanism of tumor dormancy (cytostasis) contributing to concomitant immunity.
• Understanding CI and its modulation by inflammation could lead to novel therapeutic strategies for cancer control and metastasis prevention.
• The findings suggest that non-metastatic tumors possess a stronger capacity to induce CI, highlighting potential targets for enhancing anti-tumor immunity.